Iron Supplementation in Renal Anemia

Seminars in Nephrology

Volumn 26, Issue 4, 2006, Pages 319-324

  Fishbane, Steven ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

anemia ferritin; iron

Indexed keywords

FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERROUS SULFATE; HEME IRON POLYPEPTIDE; IRON; IRON DERIVATIVE; IRON DEXTRAN; IRON POLYSACCHARIDE; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANXIETY; ARTICLE; BACKACHE; CHRONIC KIDNEY DISEASE; CONSTIPATION; DRUG ABSORPTION; DRUG FATALITY; DRUG SAFETY; DYSPEPSIA; DYSPNEA; FLUSHING; GASTROINTESTINAL IRRITATION; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS PATIENT; HUMAN; HYPOTENSION; INFECTION; IRON BALANCE; IRON DEFICIENCY; IRON THERAPY; KIDNEY DISEASE; OXIDATIVE STRESS; OXIDATIVE TISSUE INJURY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RENAL ANEMIA; SIDE EFFECT; TISSUE INJURY;

ANEMIA; ERYTHROPOIETIN, RECOMBINANT; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; RENAL DIALYSIS; SAFETY;

EID: 33750860502     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2006.05.009     Document Type: Article

References (54)

1. Fishbane S., and Maesaka J.K. Iron management in end-stage renal disease. Am J Kidney Dis 29 (1997) 319-333
2. Nissenson A.R., and Strobos J. Iron deficiency in patients with renal failure. Kidney Int Suppl 69 (1999) S18-S21
3. Diet and iron status, a study of relationships: United States, 1971-74. Data from the National Health Survey. Series 11, No. 229. Vital Health Stat 11 229:1-83, 1982
4. Otti T., Khajehdehi P., Fawzy A., et al. Comparison of blood loss with different high-flux and high-efficiency hemodialysis membranes. Am J Nephrol 21 (2001) 16-19
5. Longnecker R.E., Goffinet J.A., and Hendler E.D. Blood loss during maintenance hemodialysis. Trans Am Soc Artif Intern Organs 20A (1974) 135-140
6. Skikne B.S., Ahluwalia N., Fergusson B., et al. Effects of erythropoietin therapy on iron absorption in chronic renal failure. J Lab Clin Med 135 (2000) 452-458
7. Ervasti M., Kotisaari S., Romppanen J., et al. In patients who have stainable iron in the bone marrow an elevated plasma transferrin receptor value may reflect functional iron deficiency. Clin Lab Haematol 26 (2004) 205-209
8. Kalantar-Zadeh K., Rodriguez R.A., and Humphreys M.H. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 19 (2004) 141-149
9. Ganz T. Hepcidin-a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol 18 (2005) 171-182
10. National Kidney Foundation: NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. J Kidney Dis 37 suppl 1 (2001) S182-S238
11. Fishbane S., Kowalski E.A., Imbriano L.J., et al. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 7 (1996) 2654-2657
12. Kalantar-Zadeh K., Hoffken B., Wunsch H., et al. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 26 (1995) 292-299
13. Chuang C.L., Liu R.S., Wei Y.H., et al. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol Dial Transplant 18 (2003) 370-377
14. Tessitore N., Solero G.P., Lippi G., et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 16 (2001) 1416-1423
15. Besarab A., Amin N., Ahsan M., et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11 (2000) 530-538
16. DeVita M.V., Frumkin D., Mittal S., et al. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Nephrol 60 (2003) 335-340
17. Frykman E., Bystrom M., Jansson U., et al. Side effects of iron supplements in blood donors: Superior tolerance of heme iron. J Lab Clin Med 123 (1994) 561-564
18. Srigiridhar K., Nair K.M., Subramanian R., et al. Oral repletion of iron induces free radical mediated alterations in the gastrointestinal tract of rat. Mol Cell Biochem 219 (2001) 91-98
19. Nissenson A.R., Berns J.S., Sakiewicz P., et al. Clinical evaluation of heme iron polypeptide: Sustaining a response to rHuEPO in hemodialysis patients. Am J Kidney Dis 42 (2003) 325-330
20. Agarwal R., Vasavada N., Sachs N.G., et al. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65 (2004) 2279-2289
21. Aggarwal H.K., Nand N., Singh S., et al. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India 51 (2003) 170-174
22. Silverberg D.S., Iaina A., Peer G., et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 27 (1996) 234-238
23. Stoves J., Inglis H., and Newstead C.G. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 16 (2001) 967-974
24. Charytan C., Qunibi W., Bailie G.R., and Venofer Clinical Studies Group. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 100 (2005) c55-c62
25. Van Wyck D.B., Roppolo M., Martinez C.O., et al., United States Iron Sucrose (Venofer) Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 68 (2005) 2846-2856
26. Macdougall I.C., and Roche A. Administration of intravenous iron sucrose as a 2-minute push to CKD patients: A prospective evaluation of 2,297 injections. Am J Kidney Dis 46 (2005) 283-289
27. Collins A.J. Influence of target hemoglobin in dialysis patients on morbidity and mortality. Kidney Int Suppl 80 (2002) 44-48
28. Markowitz G.S., Kahn G.A., Feingold R.E., et al. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 48 (1997) 34-40
29. Fudin R., Jaichenko J., Shostak A., et al. Correction of uremic iron deficiency anemia in hemodialyzed patients: A prospective study. Nephron 79 (1998) 299-305
30. Macdougall I.C., Tucker B., Thompson J., et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50 (1996) 1694-1699
31. Fishbane S., and Lynn R.I. The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. Clin Nephrol 44 (1995) 238-240
32. Granolleras C., Oules R., Branger B., et al. Iron supplementation of hemodialysis patients receiving recombinant human erythropoietin therapy. In: Bauer C., Koch K.M., Scigalla P., et al. (Eds). Erythropoietin: Molecular Physiology and Clinical Applications (1993), Marcel Dekker, New York 211-218
33. Taylor J.E., Peat N., Porter C., et al. Regular, low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 11 (1996) 1079-1083
34. Sunder-Plassmann G., and Horl W.H. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10 (1995) 2070-2076
35. Sepandj F., Jindal K., West M., et al. Economic appraisal of maintenance parenteral iron administration in treatment of the anaemia in chronic haemodialysis patients. Nephrol Dial Transplant 11 (1996) 319-322
36. Allegra V., Mengozzi G., and Vasile A. Iron deficiency in maintenance hemodialysis patients: Assessment of diagnosis criteria and of three different iron treatments. Nephron 57 (1991) 175-182
37. Senger J.M., and Weiss R.J. Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment. ANNA J 23 (1996) 319-323
38. Fishbane S., Frei G.L., and Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26 (1995) 41-46
39. Vychytil A., and Haag-Weber M. Iron status and iron supplementation in peritoneal dialysis patients. Kidney Int Suppl 69 (1999) S71-S78
40. Johnson D.W., Herzig K.A., Gissane R., et al. Oral versus intravenous iron supplementation in peritoneal dialysis patients. Perit Dial Int 21 suppl 3 (2001) S231-S235
41. Fishbane S., Ungureanu V.D., Maesaka J.K., et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28 (1996) 529-534
42. Chandler G., Harchowal J., and Macdougall I.C. Intravenous iron sucrose: Establishing a safe dose. Am J Kidney Dis 38 (2001) 988-991
43. Michael B., Coyne D.W., Fishbane S., et al. Sodium ferric gluconate complex in hemodialysis patients: Adverse reactions compared to placebo and iron dextran. Kidney Int 61 (2002) 1830-1839
44. Faich G., and Strobos J. Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 33 (1999) 464-470
45. Bullen J.J., Ward C.G., and Wallis S.N. Virulence and the role of iron in Pseudomonas aeruginosa infection. Infect Immun 10 (1974) 443-450
46. Rogers H.J., Bullen J.J., and Cushnie G.H. Iron compounds and resistance to infection. Further experiments with Clostridium welchii type A in vivo and in vitro. Immunology 19 (1970) 521-538
47. Kessler M., Hoen B., Mayeux D., et al. Bacteremia in patients on chronic hemodialysis. A multicenter prospective survey. Nephron 64 (1993) 95-100
48. Hoen B., Kessler M., Hestin D., et al. Risk factors for bacterial infections in chronic haemodialysis adult patients: A multicentre prospective survey. Nephrol Dial Transplant 10 (1995) 377-381
49. Tielemans C.L., Lenclud C.M., Wens R., et al. Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine. Nephrol Dial Transplant 4 (1989) 883-887
50. Hoen B., Paul-Dauphin A., Hestin D., et al. EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 9 (1998) 869-876
51. Welch K.D., Davis T.Z., Van Eden M.E., et al. Deleterious iron-mediated oxidation of biomolecules(1) (6). Free Radic Biol Med 32 (2002) 577-583
52. Rooyakkers T.M., Stroes E.S., Kooistra M.P., et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 32 suppl 1 (2002) 9-16
53. Zager R.A., Johnson A.C., Hanson S.Y., et al. Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40 (2002) 90-103
54. Leehey D.J., Palubiak D.J., Chebrolu S., et al. Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: A pilot study. Nephrol Dial Transplant 20 (2005) 135-140